Understanding the immunopathogenesis of COVID-19:Its implication for therapeutic strategy  

作　　者：Yukihiro Shimizu 

机构地区：[1]Gastroenterology Center,Nanto Municipal Hospital,Nanto 932-0211,Toyama,Japan

出　　处：《World Journal of Clinical Cases》2020年第23期5835-5843,共9页世界临床病例杂志

摘　　要：Although 80%of individuals infected with the severe acute respiratory syndromecoronavirus 2(SARS-CoV-2)recover without antiviral treatments,the other 20%progress to severe forms of pulmonary disease,suggesting that the host’s immune response to the virus could influence the outcome of coronavirus disease 2019(COVID-19).SARS-CoV-2 infects alveolar epithelial type 2 cells expressing angiotensin-converting enzyme 2,and these infected epithelial cells recruit dendritic cells,neutrophils and monocytes/macrophages,leading to the activation of CD4+and CD8+T cells.These cells launch an antiviral immune response,but are able to completely suppress viral replication or completely eradicate virus in a limited proportion of infected patients.In other patients,viral suppression is incomplete and the numbers of circulating B and T cells are subsequently reduced by as yet unknown mechanisms.Some patients with sustained viral replication progress to a severe condition called cytokine storm.Although antiviral drug(s)should be considered early in infection to prevent progression,there have been no antiviral therapies proven to be effective for significantly inhibiting the viral replication in vivo and suppressing the progression to cytokine storm.Blocking the action of cytokines with dexamethasone or anti-interleukin-6 could have a pivotal role in treatment of those patients.Therapeutic strategy should therefore be based on viral kinetics and the immunopathology of COVID-19.

关 键 词：COVID-19 SARS-CoV-2 Immune response ANTIBODY Viral kinetics Treatment 

分 类 号：R563.1[医药卫生—呼吸系统]